E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
The sequence of events culminating in Pseudomyxoma peritonei (PMP) is thought to involve growth of an appendiceal adenoma with distension of the appendix by mucus and mucinous tumour cells. The appendix eventually ruptures. Patients undergoing the PMP surgery develop a coagulopathy predominantly characterised by reduced levels of fibrinogen, resulting in reduced whole blood clot firmness. |
|
E.1.1.1 | Medical condition in easily understood language |
Surgery performed on a cancer (tumour) in the appendix, causes decreased levels of blood clotting factor (fibrinogen). |
|
E.1.1.2 | Therapeutic area | Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Surgical Procedures, Operative [E04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10037138 |
E.1.2 | Term | Pseudomyxoma peritonei |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this study is to compare the overall (i.e. intra- and postoperative) haemostatic efficacy (ability to stop bleeding) of Octafibrin, a human blood-derived protein with that of cryoprecipitate in bleeding patients developing acquired fibrinogen deficiency during removal of tumour growth from the abdomen (cytoreductive surgery) for Pseudomyxoma Peritonei (PMP). |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives of the study are: To compare the intraoperative haemaostatic efficacy (ability to stop bleeding) of Octafibrin with that of cryoprecipitate in bleeding patients developing acquired fibrinogen deficiency during removal of tumour growth from the abdomen (cytoreductive surgery) for Pseudomyxoma Peritonei (PMP).
To compare the postoperative haemostatic efficacy by study group
To compare the capability of Octafibrin with that of cryoprecipitate to correct the acquired fibrinogen deficiency in the study population as demonstrated by an increase in Clauss plasma fibrinogen concentration.
To analyse dose and duration of fibrinogen supplementation by study group.
To assess the coagulation (change of blood to semi solid state) profiles by study group.
To analyse critical care outcome data by study group.
To determine the time to availability of Octafibrin and cryoprecipitate in the operating room.
To investigate the safety profile of Octafibrin or cryoprecipitate |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Because the need for fibrinogen supplementation will not become apparent until 60–90 minutes into the surgery, the criteria for inclusion will be assessed at two separate time points, i.e., during screening and intraoperatively.
Note: The maximum time allowed between the Screening Assessment and surgery is 1 week.
Inclusion criteria checked during the Screening Assessment: 1. Patients undergoing Sugarbaker procedure for PMP 2. Age ≥18 years 3. Voluntarily given, fully informed written and signed consent obtained before any study-related procedures are conducted 4. Patient is capable to understand and comply with the relevant aspects of the study protocol.
Inclusion criteria checked during the Intraoperative Assessments:
5. Intraoperative need for fibrinogen supplementation as assessed on the basis of ‘bleeding risk assessment’ (i.e., predicted average intraoperative blood loss ≥2L)
Patients not fulfilling inclusion criteria 5 will not be randomised and will be considered screening failures. |
|
E.4 | Principal exclusion criteria |
All exclusion criteria will be assessed during screening. Patients who meet any of the following criteria are not eligible for the study: 7. Recent history of thromboembolic disease (myocardial infarction, stroke, deep vein thrombosis, or pulmonary embolism within 2 months prior to screening) 8. Known presence of chronic infections, such as infection with HIV or hepatitis C virus, as per medical history 9. Undergoing emergency surgery 10. Surgery for other forms of peritoneal malignancy or infection 11. Receipt of fibrinogen-containing products within 14 days prior to screening. 12. Patients with any known Ccongenital or acquired coagulation disorder (e.g., von Willebrand disease, haemophilia, or severe liver disease) or a prothrombotic disorder (e.g., protein C or S deficiency) 13. Administration of a IIbIIIa antagonist within 1 day, clopidogrel within 5 days, ticagrelor within 2 days, and prasugrel within 7 days of screening 14. Direct thrombin inhibitors within 3 days and factor Xa inhibitors within 2 days of screening 15. Participation in another study within 30 days prior to screening 16. Known hypersensitivity to the study medication 17. Pregnant (based on urine pregnancy test) or lactating women |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary objective is to compare the overall (i.e. intra and postoperative) haemostatic efficacy of Octafibrin with that of cryoprecipitate in bleeding patients developing acquired fibrinogen deficiency during cytoreductive surgery for pseudomyxoma peritonei.
The primary efficacy endpoint is the overall haemostatic efficacy rating as assessed by the Independent Data Monitoring and Endpoint Adjudication Committee (IDMEAC). Haemostatic efficacy will be rated as 'excellent', 'good', 'moderate' or 'none' (4 point scale).
Ratings of 'excellent' and 'good' will be considered haemostatic success', whereas ratings of 'moderate' and 'none' will be considered hamostatic failure.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Intraoperative haemostatic efficacy of Octafibrin or cryoprecipitate is assessed at the end of surgery using the objective 4-point haemostatic efficacy scale discussed above.
Postoperative haemostatic efficacy of Octafibrin or cryoprecipiatate is assessed 24 hours ± 30 minutes after the end of surgery by the haematologist using an objective 4-point scale. |
|
E.5.2 | Secondary end point(s) |
Intra operative haemostatic efficacy of Octofibrin and cryoprecipitate in controlling intraoperative bleeding as assessed at the end of surgery by the surgeon and anaesthesiologist using an objective 4-point haemostatic efficacy scale (see response above).
Postoperative haemostatic efficacy of Octafibrin and cryoprecipitate in controlling postoperative bleeding as assessed 24 hours after the end of surgery by the haematologist using an objective 4-point scale.
Capability of Octafibrin and cryoprecipitate to correct the acquired fibrinogen deficiency as demonstrated by an increase in Clauss plasma fibrinogen concentrations after the first post-randomisation infusion (i.e. preemptive dose). |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Intraoperative haemostatic efficacy is assessed at the end of surgery by both the surgeon and the anaesthesiologist. Postoperative haemostatic efficacy is assessed 24 hours after the end of surgery by the haematologist. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The study will be considered completed when 20 evaluable patients per group have completed the planned observation period, i.e., the time between the Screening Visit and the End-of-Study Visit. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 5 |